Cabaletta Bio
CABA
84 hedge funds and large institutions have $470M invested in Cabaletta Bio in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 29 increasing their positions, 13 reducing their positions, and 16 closing their positions.
171% more call options, than puts
Call options by funds: $1.43M | Put options by funds: $529K
131% more capital invested
Capital invested by funds: $204M → $470M (+$267M)
123% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 13
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
81% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 16
18% more funds holding
Funds holding: 71 → 84 (+13)
13.19% more ownership
Funds ownership: 78.62% → 91.81% (+13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$21.7M |
| 2 |
DM
Deerfield Management
New York
|
+$20.4M |
| 3 |
BlackRock
New York
|
+$16M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$11.9M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$9.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$2.97M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.88M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$2.64M |
| 4 |
Millennium Management
New York
|
-$2.18M |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$1.36M |
CABA Hedge Fund Activity: Q2 2023 in Review
84 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Cabaletta Bio (CABA) for Q2 2023, worth a combined $470M — up 131% from $204M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new CABA positions and 16 closed out — a net gain of 13 holders — while 29 added to existing stakes and 13 trimmed.
The largest buyer was Bain Capital Life Sciences Investors, opening a new position worth an estimated $21.7M. The largest seller was Lynx1 Capital Management, cutting an estimated $2.97M.
- 84 institutional investors held Cabaletta Bio (CABA) as of Q2 2023, up from 71 in Q1 2023.
- Funds reported $470M of Cabaletta Bio stock for Q2 2023, up 131% quarter-over-quarter.
- 29 funds opened new Cabaletta Bio positions in Q2 2023 and 16 closed out, a net change of +13 holders.
- The largest Cabaletta Bio buyer in Q2 2023 was Bain Capital Life Sciences Investors, an estimated $21.7M added.
- The largest Cabaletta Bio seller in Q2 2023 was Lynx1 Capital Management, an estimated $2.97M sold.
Based on aggregated 13F filings for Q2 2023.